Bristol-Myers Squibb [BMY] vs Amgen [AMGN] Detailed Stock Comparison

Bristol-Myers Squibb

NYSE
Loading...

Amgen

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Bristol-Myers Squibb wins in 13 metrics, Amgen wins in 6 metrics, with 0 ties. Bristol-Myers Squibb appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBristol-Myers SquibbAmgenBetter
P/E Ratio (TTM)17.7322.33Bristol-Myers Squibb
Price-to-Book Ratio5.1521.63Bristol-Myers Squibb
Debt-to-Equity Ratio291.55756.65Bristol-Myers Squibb
PEG Ratio-0.770.24Bristol-Myers Squibb
EV/EBITDA6.6612.94Bristol-Myers Squibb
Profit Margin (TTM)10.58%18.96%Amgen
Operating Margin (TTM)33.68%32.73%Bristol-Myers Squibb
EBITDA Margin (TTM)33.68%32.73%Bristol-Myers Squibb
Return on Equity29.32%99.14%Amgen
Return on Assets (TTM)8.33%7.51%Bristol-Myers Squibb
Free Cash Flow (TTM)$13.94B$10.39BBristol-Myers Squibb
Dividend YieldN/A4.09%N/A
1-Year Return-15.25%-6.96%Amgen
Price-to-Sales Ratio (TTM)1.884.60Bristol-Myers Squibb
Enterprise Value$127.30B$208.88BAmgen
EV/Revenue Ratio2.675.98Bristol-Myers Squibb
Gross Profit Margin (TTM)72.52%67.20%Bristol-Myers Squibb
Revenue per Share (TTM)$23$65Amgen
Earnings per Share (Diluted)$2.49$13.37Amgen
Beta (Stock Volatility)0.360.48Bristol-Myers Squibb
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Bristol-Myers Squibb vs Amgen Stock Performance Analysis

Loading Price Chart...

Bristol-Myers Squibb
Amgen
Bristol-Myers Squibb Stock Overview | Amgen Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bristol-Myers Squibb-3.58%5.34%-3.54%-3.99%-23.27%-19.48%
Amgen-0.37%9.67%3.65%0.19%-2.72%14.70%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bristol-Myers Squibb-15.25%-34.39%-26.03%-25.57%68.37%98.83%
Amgen-6.96%29.85%25.64%98.81%427.40%286.13%

News Based Sentiment: Bristol-Myers Squibb vs Amgen

Bristol-Myers Squibb

News based Sentiment: POSITIVE

October was a notably positive month for Bristol Myers Squibb, driven by a strong earnings report, a strategic AI partnership, and proactive measures to address drug pricing. These developments, coupled with analyst upgrades and positive insider activity, suggest a strengthening investment case and improved future prospects.

View Bristol-Myers Squibb News Sentiment Analysis

Amgen

News based Sentiment: POSITIVE

Amgen experienced a highly positive month, driven by strong Q2 earnings that exceeded expectations, significant manufacturing investments, positive clinical trial results for Repatha leading to expanded FDA approval, and a subsequent increase in stock price. These factors collectively strengthen the investment case for Amgen.

View Amgen News Sentiment Analysis

Performance & Financial Health Analysis: Bristol-Myers Squibb vs Amgen

MetricBMYAMGN
Market Information
Market Cap i$89.86B$160.11B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i17,506,3403,455,190
90 Day Avg. Volume i12,232,9732,483,153
Last Close$45.73$297.40
52 Week Range$42.96 - $63.33$253.30 - $335.88
% from 52W High-27.79%-11.46%
All-Time High$81.44 (Nov 28, 2022)$346.85 (Jul 22, 2024)
% from All-Time High-43.85%-14.26%
Growth Metrics
Quarterly Revenue Growth0.01%0.09%
Quarterly Earnings Growth-0.22%0.92%
Financial Health
Profit Margin (TTM) i0.11%0.19%
Operating Margin (TTM) i0.34%0.33%
Return on Equity (TTM) i0.29%0.99%
Debt to Equity (MRQ) i291.55756.65
Cash & Liquidity
Book Value per Share (MRQ)$8.57$13.80
Cash per Share (MRQ)$6.68$14.91
Operating Cash Flow (TTM) i$15.90B$12.01B
Levered Free Cash Flow (TTM) i$16.19B$10.42B
Dividends
Last 12-Month Dividend Yield iN/A4.09%
Last 12-Month Dividend iN/A$11.64

Valuation & Enterprise Metrics Analysis: Bristol-Myers Squibb vs Amgen

MetricBMYAMGN
Price Ratios
P/E Ratio (TTM) i17.7322.33
Forward P/E i6.2814.44
PEG Ratio i-0.770.24
Price to Sales (TTM) i1.884.60
Price to Book (MRQ) i5.1521.63
Market Capitalization
Market Capitalization i$89.86B$160.11B
Enterprise Value i$127.30B$208.88B
Enterprise Value Metrics
Enterprise to Revenue i2.675.98
Enterprise to EBITDA i6.6612.94
Risk & Other Metrics
Beta i0.360.48
Book Value per Share (MRQ) i$8.57$13.80

Financial Statements Comparison: Bristol-Myers Squibb vs Amgen

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BMYAMGN
Revenue/Sales i$12.27B$8.15B
Cost of Goods Sold i$3.37B$2.97B
Gross Profit i$8.90B$5.18B
Research & Development i$2.58B$1.49B
Operating Income (EBIT) i$3.77B$1.18B
EBITDA i$5.26B$4.08B
Pre-Tax Income i$1.77B$1.97B
Income Tax i$460.00M$243.00M
Net Income (Profit) i$1.31B$1.73B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BMYAMGN
Cash & Equivalents i$10.88B$8.81B
Total Current Assets i$30.78B$26.93B
Total Current Liabilities i$24.07B$23.01B
Long-Term Debt i$47.51B$54.01B
Total Shareholders Equity i$17.45B$6.21B
Retained Earnings i$16.11B$-27.14B
Property, Plant & Equipment i$1.22BN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BMYAMGN
Operating Cash Flow i$2.11B$1.71B
Capital Expenditures iN/A$-411.00M
Free Cash Flow i$1.69B$980.00M
Debt Repayment iN/A$-2.50B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBMYAMGN
Shares Short i29.47M13.20M
Short Ratio i3.056.63
Short % of Float i0.01%0.02%
Average Daily Volume (10 Day) i17,506,3403,455,190
Average Daily Volume (90 Day) i12,232,9732,483,153
Shares Outstanding i2.03B537.00M
Float Shares i2.03B536.99M
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.83%0.84%

Dividend Analysis & Yield Comparison: Bristol-Myers Squibb vs Amgen

MetricBMYAMGN
Last 12-Month Dividend iN/A$11.64
Last 12-Month Dividend Yield iN/A4.09%
3-Year Avg Annual Dividend iN/A$9.51
3-Year Avg Dividend Yield iN/A0.80%
3-Year Total Dividends iN/A$28.54
Ex-Dividend DateN/AAug 22, 2025